CRISM Therapeutics Corporation

CRTX.L · LSE
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-£607-£1,923-£2,115-£1,302
Dep. & Amort.£16£0£0£0
Deferred Tax£0£0£0£0
Stock-Based Comp.£0£0£0£0
Change in WC-£55£0£0£0
Other Non-Cash-£287-£847-£1,400-£531
Operating Cash Flow-£933-£2,770-£2,726-£1,095
Investing Activities
PP&E Inv.-£28£0-£265-£310
Net Acquisitions£2,356£0£114£0
Inv. Purchases£0£0£0£0
Inv. Sales/Matur.£0£0£0£4,462
Other Inv. Act.£0£34,931-£360£1,885
Investing Cash Flow£2,328£34,931-£511£6,038
Financing Activities
Debt Repay.£0£0£0£0
Stock Issued£102£0£345£0
Stock Repurch.£0£0£0£0
Dividends Paid-£47-£31,447£0£0
Other Fin. Act.-£122£0£623£0
Financing Cash Flow-£67-£31,447£968£0
Forex Effect-£47£46£0-£313
Net Chg. in Cash£1,281£760-£3,058£3,892
Supplemental Information
Beg. Cash£1£3,624£4,933£2,041
End Cash£1,282£4,384£2,896£4,933
Free Cash Flow-£961-£2,770-£2,992-£1,405